Even after adjustment to tumour size, sHR status, HER2 status, grading, and nodal status, patients with a high uPA/PAI-1 status had significantly higher risk of recurrence compared to those with a low uPA/PAI-1 status (HR 2.60, 95% CI 1.293–5.227) (Table 3, Fig. 3). This evidence concerns the gene ERBB2 and neoplasm.